期刊
NATURE REVIEWS NEUROLOGY
卷 15, 期 6, 页码 314-315出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/s41582-019-0178-0
关键词
-
Studies in melanoma and lung cancer indicate that shifting use of immune checkpoint inhibition from palliative stages to the neoadjuvant setting improves response rates and patient outcomes. Three studies now show that neoadjuvant programmed cell death 1 (PD1) inhibition modulates the immune tumour microenvironment - but does this effect translate into a real patient benefit?
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据